Search Results

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 for redemption on Friday, June 14, 2024.

Collegium Pharmaceutical, Inc. announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024.

Collegium Pharmaceutical, Inc. reported its financial results for the quarter ended March 31, 2024, and provided a corporate update.

Collegium Pharmaceutical, Inc. announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that the U.S. Food and Drug Administration has granted pediatric exclusivity for Nucynta® and Nucynta® ER.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, announced that effective May 24, 2024, Joe Ciaffoni will step down as President and Chief Executive Officer of the Company.

Collegium Pharmaceutical, Inc. today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.